Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications

European Review for Medical and Pharmacological Sciences

Volumn 11, Issue 5, 2007, Pages 301-308

  de Rosa, G ^a   Pardeo, M ^a   Rigante, Donato ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cardiovascular complications; Kawasaki syndrome

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DIPYRIDAMOLE; IMMUNOGLOBULIN; INFLIXIMAB; LOW MOLECULAR WEIGHT HEPARIN; METHYLPREDNISOLONE; WARFARIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY ANEURYSM; CORONARY ARTERY DILATATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; ECHOCARDIOGRAPHY; HEART TRANSPLANTATION; HUMAN; INCIDENCE; LOW DRUG DOSE; MONOTHERAPY; MUCOCUTANEOUS LYMPH NODE SYNDROME; PLASMAPHERESIS; PROGNOSIS; REVIEW; SINGLE DRUG DOSE; STENT; THROMBOSIS PREVENTION; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CORONARY DISEASE; FIBRINOLYTIC AGENTS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 36749037333     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. TAUSERT KA, ROWLEY AH, SHULMAN ST. Nationwide survey of Kawasaki disease and acute rheumatic fever. J Pediatr 1991; 119: 279-282.
2. NAKAMURA Y, FUJITA Y, NAGAI M, YANAGAWA H, IMADA Y, OKAWA S, KAWASAKI T, KATO H. Cardiac sequelae of Kawasaki disease in Japan: statistical analysis. Pediatrics 1991; 88: 1144-1147.
3. STAPP J, MARSHALL GS. Fulfillment of diagnostic criteria in Kawasaki disease. Southern Med J 2000; 93: 44-47.
4. JOFFE A, KABANI A, JADAVJI T. Atypical and complicated Kawasaki disease in infants. Do we need criteria? West J Med 1995; 162: 322-327.
5. NEWBURGER JW. Treatment of Kawasaki disease. Lancet 1996; 347: 1128.
6. BROGAN PA, BOSE A, BURGNER D, SHINGADIA D, TULLOH R, MICHIE C, KLEIN N, BOOY R, LEVIN M, DILLON MJ. Kawasaki disease: an evidence based approach to diagnosis, treatment and proposals for future research. Arch Dis Child 2002; 86: 286-290.
7. LAUPLAND KB, DELE DAVIES H. Epidemiology, etiology and management of Kawasaki disease: state of the art. Pediatr Cardiol 1999; 20: 177-183.
8. NAKASHIMA L, EDWARDS DL. Treatment of Kawasaki disease. Clin Pharm 1990; 9: 755-762.
9. TERAI M, SHULMAN ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997; 131: 888-893.
10. HSICH KS, WENG KP, LIN CC, HUANG TC, LEE CL, HUANG SM. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited. Pediatrics 2004; 114: e689-e693.
11. NEWBURGER JW, TAKAHASHI M, GERBER MA, GEWITZ MH, TANI LY, BURNS JC, SHULMAN ST, BOLGER AF, FERRIERI P, BALTIMORE RS, WILSON WR, BADDOUR LM, LEVISON ME, PALLASCH TJ, FALACE DA, TAUBERT KA; COMMITTEE ON RHEUMATIC FEVER, ENDOCARDITIS AND KAWASAKI DISEASE; COUNCIL ON CARDIOVASCULAR DISEASE IN THE YOUNG; AMERICAN HEART ASSOCIATION; AMERICAN ACADEMY OF PEDIATRICS. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004; 110: 2747-2771.
12. KATO H, SUGIMURA T, AKAGI T, SATO N. HASHINO K, MAENO Y, KAZUE T, ETO G, YAMAKAWA R. Long-term consequences of Kawasaki disease. A 10 to 21 year follow-up study of 594 patients. Circulation 1996; 94: 1379-1385.
13. DAJANI AS, TAUBERT KA, GERBER MA, SHULMAN ST, FERRIERI P, FREED M, TAKAHASHI M, BIERMAN FZ, KARCHMER AW, WILSON W, PETER G, DURACK DT, RAHIMTOOLA SH, MEMBERS OF THE COMMITTEE ON RHEUMATIC FEVER, ENDOCARDITIS AND KAWASAKI DISEASE, COUNCIL ON CARDIOVASCULAR DISEASE IN THE YOUNG, AMERICAN HEART ASSOCIATION. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993; 87: 1776-1780.
14. FUJIWARA H, HAMASHIMA Y. Pathology of the heart in Kawasaki disease: Pediatrics 1978; 61: 100-107.
15. YUTANI C, OKANO K, KAMIYA T, OGUCHI K, KOZUKA T, OTA M, ONISHI S. Histopathological study on right endomyocardial biopsy of Kawasaki disease. Br Heart J 1980; 43: 589-592.
16. MATSUURA H, ISHIKITA T, YAMAMOTO S, UMEZAWA T, ITO R, HASHIGUCHI R, SAJI T, MATSUO N, TAKANO M. Gallium-67 myocardial imaging for the detection of myocarditis in the acute phase of Kawasaki disease (mucocutaneous lymph node syndrome: the usefulness of single photon emission computed tomography. Br Heart J 1987; 58: 385-392.
17. ANDERSON TM, MEYER RA, KAPLAN S. Long-term echocardiographic evaluation of cardiac size and function in patients with Kawasaki disease. Am Heart J 1985; 110: 107-115.
18. HIRAISHI S, YASHIRO K, OGUCHI K KUSANO S, ISHII K, NAKAZAWA K. Clinical course of cardiovascular involvement in the mucocutaneous lymph node syndrome. Relation between clinical signs of carditis and development of coronary arterial aneurysm. Am J Cardiol 1981; 47: 323-330.
19. TSE SM, SILVERMAN ED, MCCRINDLE BW, YEUNG RS. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. J Pediatr 2002; 140: 450-455.
20. NAGASHIMA M, MATSUSHIMA M, MATSUOKA H, OGAWA A, OKUMURA N. High-dose gammaglobulin therapy for Kawasaki disease. J Pediatr 1987; 110: 710-712.
21. DURONGPISITKUL K, GURURAI VJ, PARK JM, MARTIN CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995; 96: 1057-1061.
22. WILDER MS, PALINKAS LA, KAO AS, BASTIAN JF, TURNER CL, BURNS JC. Delayed diagnosis by physicians contributes to the development of coronary artery aneurysms in children with Kawasaki syndrome. Pediatr Infect Dis J 2007; 26: 256-260.
23. SHACKELFORD PG, STRAUSS AW. Kawasaki syndrome. N Engl J Med 1991; 324: 1664-1666.
24. CURTIS N. Kawasaki disease. Br Med J 1997; 315: 322-323.
25. SUNDEL RP, BURNS JC, BAKER A, BEISER AS, NEWBURGER JW. Gamma globulin re-treatment in Kawasaki disease. J Pediatr 1993; 123: 657-659.
26. FREEMAN AF, SHULMAN ST. Refractory Kawasaki disease. Pediatr Infect Dis J 2004; 23: 463-464.
27. HAN RK, SILVERMAN ED, NEWMAN A, MCCRINDLE BW. Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in Kawasaki disease. Arch Pediatr Adolesc Med 2000; 154: 694-699.
28. KATO H, KOIKE S, YOKOYAMA T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979; 63: 175-179.
29. WRIGHT DA, NEWBURGER JW, BAKER A, SUNDEL RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996; 128: 146-149.
30. NEWBURGER JW. Treatment of Kawasaki disease: corticosteroids revisited. J Pediatr 1999; 135: 411-413.
31. AL-MAYOUF SM. The use of corticosteroid therapy in refractory Kawasaki patients. Clin Rheumatol 2004; 23: 11-13.
32. SHULMAN ST. Is there a role for corticosteroids in Kawasaki disease? J Pediatr 2003; 142: 601-603.
33. SUNDEL RP, BAKER AL, FULTON DR, Newburger JW. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr 2003; 142: 611-616.
34. BURAS JC, MASON WH, HAUGER SB, JANAI H, BASTIAN JF, WOHRLEY JD, BALFOUR I, SHEN CA, MICHEL ED, SHULMAN ST, MELISH ME. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005; 146: 662-667.
35. BURNS JC, KUSHNER HI, BASTIAN JF, SHIKE H, SHIMIZU C, MATSUBARA T, TURNER CL. Kawasaki disease: a brief history. Pediatrics 2000; 106: e27.
36. NAKAMURA Y, YANAGAWA H. A case-control study of recurrent Kawasaki disease using the database of the nationwide surveys in Japan. Eur J Pediatr 1996; 155: 303-307.
37. MICHIE C, KINSLER V, TULLOH R, DAVIDSON S. Recurrent skin peeling following Kawasaki disease. Arch Dis Child 2000; 83: 353-355.
38. MIURA M, KATADA Y, ISHIHARA J. Time interval of measles vaccination in patients with Kawasaki disease treated with additional intravenous immune globulin. Eur J Pediatr 2004; 163: 25-29.
39. DAJANI AS, TAUBERT KA, TAKAHASHI M, BIERMAN FZ, FREED MD, FERRIERI P, GERBER M, SHULMAN ST, KARCHMER AW, WILSON W, PETER G, DURACK DT, RAHIMTOOLA SH. Guidelines for long-term management of patients with Kawasaki disease. Report from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 1994; 89: 916-922.
40. DE ZORZI A, COLAN SD, GAUVREAU K, BAKER AL, SUNDEL RP, NEWBURGER JW. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr 1998; 133: 254-258.
41. MCMORROW TUOHY AM, TANI LY, CETTA F, LEVAN MB, EIDEM BW, VAN BUREN P, WILLIAMS RV, SHADDY RE, TUOHY RP, MINICH LL. How many echocardiograms are necessary for follow-up evaluation of patients with Kawasaki disease? Am J Cardiol 2001; 88: 328-330.
42. SCOTT JS, ETTEDGUI JA, NECHES WH. Cost-effective use of echocardiography in children with Kawasaki disease. Pediatrics 1999; 104: e57.
43. CHEUNG YF, YUNG TC, TAM SC, HO MH, CHAU AK. Novel and traditional cardiovascular risk factors in children after Kawasaki disease: implication for premature atherosclerosis. J Am Coll Cardiol 2004; 43: 120-124.
44. NEWBURGER JW, BURNS JC, BEISER AS, LO SSCALZO J. Altered lipid profile after Kawasaki syndrome. Circulation 1991; 84: 625-631.
45. DHILLON R, CLARKSON P, DONALD AE, POWE AJ, NASH M, NOVELLI V, DILLON MJ, DEANFIELD JE. Endothelial dysfunction late after Kawasaki disease. Circulation 1996; 94: 2103-2106.
46. WANG-CLOW F, FOX NI, CANNON CP, GIBSON CM, BERIOU S, BLUHMKI E, DANAYS T, BRAUNWALD E, VAN DER WERF F, STUMP DC. Determination of a weight-ad-justed dose of TNK-tissue plasminogen activator. Am Heart J 2001; 141: 33-40.
47. ISHII M, UENO T, AKAGI T, BABA K, HARADA K, HAMAOKA K, KATO H, TSUDA E, UEMURA S, SAJI T, OGAWA S, ECHIGO S, YAMAGUCHI T, KATO H; RESEARCH COMMITTEE OF MINISTRY OF HEALTH, LABOUR AND WELFARE. "Study of treatment and long-term management in Kawasaki disease". Guidelines for catheter intervention in coronary artery lesion in Kawasaki disease. Pediatr Int 2001; 43: 558-562.
48. WILLIAMS RV, WILKE VM, TANI LY, MINICH LL. Does abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? Pediatrics 2002; 109; e4.
49. SUBCOMMITTEE OF CARDIOVASCULAR SEOUELAE, SUBCOMMITTEE OF SURGICAL TREATMENT, KAWASAKI DISEASE RESEARCH COMMITTEE. Guidelines for treatment and management of cardiovascular sequelae in Kawasaki disease. Heart Vessels 1987; 3: 50-54.
50. CHECCHIA PA, PAHL E, SHADDY RE, SHULMAN ST. Cardiac transplantation for Kawasaki disease. Pediatrics 1997; 100: 695-699.
51. TAKAHASHI M, MASON W, LEWIS AB. Regression of coronary aneurysms in patients with Kawasaki syndrome. Circulation 1987; 75: 387-394.
52. FUJIWARA T, FUJIWARA H, HAMASHIMA Y. Size of coronary aneurysm as a determinant factor of the prognosis in Kawasaki disease: clinico-pathologic study of coronary aneurysms. Prog Clin Biol Res 1987; 250: 519-520.
53. NAKANO H, UEDA K, SAITO A, NOJIMA K. Repeated quantitative angiograms in coronary arterial aneurysm in Kawasaki disease. Am J Cardiol 1985; 56: 846-851.
54. NEWBURGER JW, BURNS JC. Kawasaki disease. Vasc Med 1999; 4: 187-202.